Ivapace 5mg Tablet contains Ivabradine, a selective inhibitor of the If current in the sinoatrial node, used primarily for the management of chronic stable angina pectoris and heart failure. Ivabradine works by reducing the heart rate without affecting myocardial contractility or intracardiac conduction, thereby decreasing myocardial oxygen demand and improving exercise tolerance in patients with angina. It is indicated for patients with stable angina who have a normal sinus rhythm and a resting heart rate of at least 70 beats per minute, particularly when beta-blockers are contraindicated or insufficient. Additionally, Ivapace is utilized in patients with chronic heart failure with reduced ejection fraction to reduce the risk of hospitalization for worsening heart failure. The recommended dosage should be individualized based on heart rate response, with regular monitoring to avoid bradycardia. Common adverse effects include luminous phenomena, bradycardia, and headache, while contraindications include acute decompensated heart failure, severe hypotension, and sinoatrial block. Ivapace should be used cautiously in patients with hepatic impairment and in combination with other heart rate-lowering agents. Overall, Ivapace 5mg Tablet offers a targeted therapeutic option for heart rate reduction in appropriate cardiovascular conditions, enhancing patient outcomes when used under medical supervision.